Search Results - "Kühnast, S."

Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE3Leiden.CETP mice--a translational model for atherosclerosis by Gierman, L M, Kühnast, S, Koudijs, A, Pieterman, E J, Kloppenburg, M, van Osch, G J V M, Stojanovic-Susulic, V, Huizinga, T W J, Princen, H M G, Zuurmond, A-M

“…Hypercholesterolaemia, a risk factor for atherosclerosis (ATH), has been suggested to have a role in the development of osteoarthritis (OA). To test this…”
Get more information

Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought by Kozijn, A.E., Gierman, L.M., van der Ham, F., Mulder, P., Morrison, M.C., Kühnast, S., van der Heijden, R.A., Stavro, P.M., van Koppen, A., Pieterman, E.J., van den Hoek, A.M., Kleemann, R., Princen, H.M.G., Mastbergen, S.C., Lafeber, F.P.J.G., Zuurmond, A.-M., Bobeldijk, I., Weinans, H., Stoop, R.

“…Human cohort studies have demonstrated a role for systemic metabolic dysfunction in osteoarthritis (OA) pathogenesis in obese patients. To explore the…”
Get full text

Alirocumab, monoclonal antibody to PCSK9, dose-dependently decreases atherosclerosis, improves plaque stability and shows additive effects with atorvastatin in apoe3leiden.cetp mice by Van der Hoorn, J.W.A, Kühnast, S, Pieterman, E.J, Van den Hoek, A.M, Sasiela, W.J, Gusarova, V, Peyman, A, Schaefer, H.L, Schwahn, U, Jukema, J.W, Princen, H.M.G

Get full text

Osteoarthritis development is induced by increased dietary cholesterol in APOE3Leiden.CETP mice, a translational model for atherosclerosis, and can be inhibited by atorvastatin by Gierman, L.M, Kühnast, S, Koudijs, A, Pieterman, E.J, Kloppenburg, M, van Osch, G.J, Stojanovic-Susulic, V, Huizinga, T.W, Princen, H.M, Zuurmond, A.-M

Get full text

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin by Kühnast, Susan, van der Tuin, Sam J L, van der Hoorn, José W A, van Klinken, Jan B, Simic, Branko, Pieterman, Elsbet, Havekes, Louis M, Landmesser, Ulf, Lüscher, Thomas F, Willems van Dijk, Ko, Rensen, Patrick C N, Jukema, J Wouter, Princen, Hans M G

“…The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary…”
Get full text

PRM219 - Indirect Comparisons in Benefit Assessment by Kühnast, S, Schiffner-Rohe, J, Rahnenführer, J, Leverkus, F

Get full text

Indirect Comparisons in Benefit Assessment by Kühnast, S, Schiffner-Rohe, J, Rahnenführer, J, Leverkus, F

Get full text

181 ADDITIVE EFFECTS OF NIACIN ON TOP OF SIMVASTATIN TREATMENT IN REDUCING ATHEROSCLEROSIS IN APOE3LEIDEN.CETP MICE by Louwe, M., Kühnast, S., Smit, J., Havekes, L., Rensen, P., van der Hoorn, J., Princen, H., Jukema, W.

Get full text